ZA9610780B - Injectable quinolone formulations. - Google Patents

Injectable quinolone formulations.

Info

Publication number
ZA9610780B
ZA9610780B ZA9610780A ZA9610780A ZA9610780B ZA 9610780 B ZA9610780 B ZA 9610780B ZA 9610780 A ZA9610780 A ZA 9610780A ZA 9610780 A ZA9610780 A ZA 9610780A ZA 9610780 B ZA9610780 B ZA 9610780B
Authority
ZA
South Africa
Prior art keywords
injectable
quinolone
formulations
quinolone formulations
injectable quinolone
Prior art date
Application number
ZA9610780A
Other languages
English (en)
Inventor
Wayne Alan Boettner
Peter Connor Canning
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9610780(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ZA9610780B publication Critical patent/ZA9610780B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9610780A 1995-12-21 1996-12-20 Injectable quinolone formulations. ZA9610780B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (1)

Publication Number Publication Date
ZA9610780B true ZA9610780B (en) 1998-06-22

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610780A ZA9610780B (en) 1995-12-21 1996-12-20 Injectable quinolone formulations.

Country Status (42)

Country Link
US (1) US5811130A (cs)
EP (1) EP0868183B1 (cs)
JP (1) JP3416145B2 (cs)
KR (1) KR100402570B1 (cs)
CN (1) CN1104899C (cs)
AP (1) AP706A (cs)
AR (1) AR005147A1 (cs)
AT (1) ATE212551T1 (cs)
AU (1) AU709474B2 (cs)
BG (1) BG63933B1 (cs)
BR (1) BR9612230A (cs)
CA (1) CA2239352C (cs)
CO (1) CO4480098A1 (cs)
CZ (1) CZ293747B6 (cs)
DE (1) DE69618987T2 (cs)
DK (1) DK0868183T3 (cs)
DZ (1) DZ2146A1 (cs)
EG (1) EG24071A (cs)
ES (1) ES2167609T3 (cs)
GT (1) GT199600098A (cs)
HR (1) HRP960607B1 (cs)
HU (1) HU227918B1 (cs)
IL (1) IL124454A (cs)
IS (1) IS2010B (cs)
MA (1) MA24035A1 (cs)
MX (1) MX9805026A (cs)
MY (1) MY117109A (cs)
NO (1) NO315734B1 (cs)
NZ (2) NZ501160A (cs)
OA (1) OA10697A (cs)
PE (1) PE25798A1 (cs)
PL (1) PL186795B1 (cs)
PT (1) PT868183E (cs)
RS (1) RS49523B (cs)
RU (1) RU2141827C1 (cs)
SI (1) SI0868183T1 (cs)
SK (1) SK284412B6 (cs)
TN (1) TNSN96163A1 (cs)
TW (1) TW449475B (cs)
UA (1) UA56151C2 (cs)
WO (1) WO1997023217A1 (cs)
ZA (1) ZA9610780B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
EP1255565A1 (de) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
BR0312111A (pt) * 2002-06-26 2005-03-29 Pharmacia Corp Formulação estável, lìquida, parenteral de parecoxib
JPWO2006004028A1 (ja) * 2004-07-02 2008-04-24 第一製薬株式会社 キノロン含有医薬組成物
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP5279487B2 (ja) * 2005-05-18 2013-09-04 エムペックス・ファーマシューティカルズ・インコーポレーテッド エアロゾル化フルオロキノロンおよびその使用
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
DK1991201T3 (en) * 2006-02-10 2018-06-14 Pari Pharma Gmbh SPRAY ANTIBIOTICS FOR INHALATION THERAPY
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010643A1 (de) 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
HRP20180600T1 (hr) 2008-10-07 2018-06-01 Horizon Orphan Llc Aerosol-kinolinske formulacije za poboljšanu farmakokinetiku
DK2346509T3 (da) 2008-10-07 2020-08-03 Horizon Orphan Llc Inhalation af levofloxacin til at reducere lungeinflammation
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2016195020A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
WO2016195021A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
EP3579820B1 (en) * 2017-02-13 2021-04-28 Bayer Animal Health GmbH Liquid composition containing pradofloxacin
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US523505A (en) * 1894-07-24 Island
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
ES2102393T3 (es) * 1989-12-29 1997-08-01 Abbott Lab Complejos de acido quinolona carboxilico--ion metalico--acido.
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
DE69102900T3 (de) * 1990-02-14 1998-04-09 Otsuka Pharma Co Ltd Brausemischung, deren Herstellung sowie Verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
CZ193098A3 (cs) 1999-05-12
UA56151C2 (uk) 2003-05-15
KR19990076617A (ko) 1999-10-15
IL124454A0 (en) 1998-12-06
NO982842D0 (no) 1998-06-19
BG102542A (en) 1999-06-30
HUP9903726A2 (hu) 2000-04-28
PL186795B1 (pl) 2004-02-27
TNSN96163A1 (fr) 2005-03-15
WO1997023217A1 (en) 1997-07-03
MA24035A1 (fr) 1997-07-01
TW449475B (en) 2001-08-11
RU2141827C1 (ru) 1999-11-27
CA2239352A1 (en) 1997-07-03
EG24071A (en) 2008-05-11
YU69096A (sh) 1999-06-15
HRP960607A2 (en) 1998-06-30
DE69618987D1 (de) 2002-03-14
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
AP9600898A0 (en) 1997-01-31
NZ320545A (en) 2000-03-27
ATE212551T1 (de) 2002-02-15
SK80798A3 (en) 1999-09-10
PL328001A1 (en) 1999-01-04
OA10697A (en) 2001-05-04
CO4480098A1 (es) 1997-07-09
CZ293747B6 (cs) 2004-07-14
EP0868183B1 (en) 2002-01-30
BG63933B1 (bg) 2003-07-31
PT868183E (pt) 2002-06-28
JPH11501331A (ja) 1999-02-02
DK0868183T3 (da) 2002-03-25
EP0868183A1 (en) 1998-10-07
CN1104899C (zh) 2003-04-09
AR005147A1 (es) 1999-04-14
IS4755A (is) 1998-05-25
SK284412B6 (sk) 2005-03-04
HRP960607B1 (en) 2002-06-30
MX9805026A (es) 1998-09-30
DE69618987T2 (de) 2002-11-21
HU227918B1 (en) 2012-06-28
BR9612230A (pt) 1999-07-13
MY117109A (en) 2004-05-31
SI0868183T1 (en) 2002-04-30
CA2239352C (en) 2002-06-04
HUP9903726A3 (en) 2001-01-29
GT199600098A (es) 1998-06-12
JP3416145B2 (ja) 2003-06-16
PE25798A1 (es) 1998-05-21
CN1205636A (zh) 1999-01-20
NO982842L (no) 1998-06-19
IS2010B (is) 2005-05-13
US5811130A (en) 1998-09-22
NO315734B1 (no) 2003-10-20
KR100402570B1 (ko) 2003-12-18
AU7328996A (en) 1997-07-17
RS49523B (sr) 2006-10-27
ES2167609T3 (es) 2002-05-16
DZ2146A1 (fr) 2002-10-23
NZ501160A (en) 2001-10-26
IL124454A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
ZA9610780B (en) Injectable quinolone formulations.
ZA967034B (en) Pharmaceutical compositions.
ZA9711508B (en) Rapidly disintegrable pharmaceutical composition.
ZA9710927B (en) Pharmaceutical composition.
ZA974735B (en) Pharmaceutical compositions.
ZA9710429B (en) Broad-spectrumδ-endotoxins.
ZA965190B (en) Pharmaceutical composition.
ZA9710071B (en) Pharmaceutical composition.
ZA979199B (en) Aminothiophenecarboxamides.
ZA976168B (en) 3-Ureido-pyridofurans and -pyridothiophenes.
ZA977206B (en) Arylalkanoylpyridazines.
ZA975261B (en) Composition.
ZA978304B (en) 3-alkyl-3-phenyl-piperidines.
ZA976815B (en) Vaccine composition.
ZA976492B (en) Substituted pyrroles.
ZA977104B (en) Pharmaceutical compositions.
ZA968081B (en) Pharmaceutical composition.
ZA966773B (en) Sulfonyl-or sulfinyl-benzoylguanidin derivate.
ZA979725B (en) Benzoaxozole derivative.
ZA976487B (en) Substituted pyrroles.
ZA97572B (en) 1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines.
ZA972602B (en) Pharmaceutical compositions.
ZA975906B (en) Syringes.
ZA976022B (en) Cycloalkano-pyridines.
ZA971466B (en) Endothelin-receptor-antagonists.